Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.

Sandison T, Ong V, Lee J, Thye D.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01627-16. doi: 10.1128/AAC.01627-16. Print 2017 Feb.

2.

Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.

Jandourek A, Smith A, Llorens L, Thye DA, Eckburg PB, Friedland HD.

Hosp Pract (1995). 2014 Feb;42(1):75-8. doi: 10.3810/hp.2014.02.1094.

PMID:
24566599
3.

Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections.

Talbot GH, O'Neal T, Das AF, Thye D.

Antimicrob Agents Chemother. 2013 Jan;57(1):647-50. doi: 10.1128/AAC.01344-12. Epub 2012 Nov 5.

4.

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.

Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D.

Antimicrob Agents Chemother. 2012 May;56(5):2231-6. doi: 10.1128/AAC.05738-11. Epub 2012 Feb 6.

5.

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.

Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):258-70. doi: 10.1128/AAC.05005-11. Epub 2011 Oct 24.

6.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

PMID:
21482568
7.

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 1 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096.

PMID:
21482566
8.

Review of ceftaroline fosamil microbiology: integrated FOCUS studies.

Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii45-51. doi: 10.1093/jac/dkr098. Review.

PMID:
21482569
9.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Biek D, Critchley IA, Riccobene TA, Thye DA.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251. Review.

PMID:
21115457
10.

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 2 investigators.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv53-iv65. doi: 10.1093/jac/dkq255.

PMID:
21115455
11.

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51. doi: 10.1093/jac/dkq254.

PMID:
21115454
12.

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D.

Clin Infect Dis. 2010 Dec 15;51(12):1395-405. doi: 10.1086/657313. Epub 2010 Nov 10. Erratum in: Clin Infect Dis. 2011 Apr 1;52(7):967.

PMID:
21067350
13.

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D.

Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827.

PMID:
20695801
14.

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.

Talbot GH, Thye D, Das A, Ge Y.

Antimicrob Agents Chemother. 2007 Oct;51(10):3612-6. Epub 2007 Aug 6.

15.

Transforming growth factor-beta, osteogenin, and bone morphogenetic protein-2 inhibit intercellular communication and alter cell proliferation in MC3T3-E1 cells.

Rudkin GH, Yamaguchi DT, Ishida K, Peterson WJ, Bahadosingh F, Thye D, Miller TA.

J Cell Physiol. 1996 Aug;168(2):433-41.

PMID:
8707879
16.

The isolation of a fibroblast growth inhibitor associated with perigraft seroma.

Ahn SS, Williams DE, Thye DA, Cheng KQ, Lee DA.

J Vasc Surg. 1994 Aug;20(2):202-8.

PMID:
8040943

Supplemental Content

Support Center